Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hydroxychloroquine is a safer derivative of chloroquine. Hydroxychloroquine is an immunosuppressive and anti-parasite drug indicated for the treatment or prevention of malaria, although the drug is ineffective for chloroquine-resistant malaria. Hydroxychloroquine is also recommended for autoimmune diseases such as systemic and discoid lupus erythematosus, and rheumatoid arthritis (acute and severe), when other medications fail to work or cannot be used.

Recently, hydroxychloroquine has attracted attention due to its effectiveness in treating the patients with coronavirus disease (COVID 19). Reports from China demonstrated chloroquine can possibly inhibit SARS-CoV-2 in vitro. The drug showed efficacy in treating patients with coronavirus disease (COVID 19). Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The U.S. Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19).

Major players such as operating in hydroxychloroquine market include, Amneal, Dr. Reddy's Laboratories, Laurus Labs, Mylan, Prasco Labs, Sandoz, Teva, and Zydus Cadila. According to Globes, in March 2020, manufacturers of generic version of hydroxychloroquine dominated the hydroxychloroquine market in 2019 in the U.S. The major market share holders in the hydroxychloroquine market were Prasco (30.5%), followed by Sandoz (28.2%), Zydos Cadila (14%), and Teva Pharmaceutical Industries Ltd. (9.2%).

The global hydroxychloroquine market size is estimated to be valued at US$ 484.9 million in 2019 and is expected to exhibit a CAGR of 45.7% over the forecast period (2020-2027).

Figure 1. Global Hydroxychloroquine Market Value (US$ Mn), by Region, 2019

Hydroxychloroquine  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing incidence of disease outbreaks is expected to propel the market growth over the forecast period

The increasing incidence of disease outbreaks such as coronavirus is escalating demand for advanced diagnostic measures, which is expected to boost growth of the hydroxychloroquine market. For instance, the coronavirus disease (COVID 19) is the most recent outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID 19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO), around 823,626 cases of the coronavirus disease (COVID 19) were reported on April 1, 2020, globally. 

Figure 2. Global Hydroxychloroquine Market Share (%), by Disease Indication

Hydroxychloroquine  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing demand of hydroxychloroquine is expected to drive the market growth over the forecast period

The increasing demand for hydroxychloroquine due to sudden outbreak of coronavirus disease (COVID 19) is expected to boost the market growth over the forecast period. For instance, on March 30, 2020, Novartis International AG announced that its generics and biosimilars division, Sandoz, started the shipping of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for controlled clinical studies. The purpose of the study is to evaluate the effectiveness of hydroxychloroquine in people who have tested positive for coronavirus disease (COVID 19). On the same day, Sandoz donated 20,000 doses of hydroxychloroquine to the University of Washington for a COVID-19 PEP clinical trial.

Hydroxychloroquine Market Report Coverage
Report Coverage Details
Base Year: 2019 Market Size in 2019: USD 484.9 million
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 45.7% 2027 Value Projection: USD 6,781.1 million
Geographies covered:
  • North America: U.S.,Canada.
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, UK, Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • GCC Countries: Israel, South Africa, North Africa, Central Africa
Segments covered:
  • Disease Indication
    • Malaria
    • Coronavirus Disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Companies covered (8):

Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.

Growth Drivers:
  • Disease outbreaks such as coronavirus disease (COVID 19)
  • High prevalence of malaria and rheumatoid arthritis
  • Increasing product launches and approvals
Restraints & Challenges:
  • Lack of evidences associated with the treatment coronavirus disease (COVID 19)

Key Players

Major players operating in the global hydroxychloroquine market include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.

Hydroxychlorquine has exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.

Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2020, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).

Key features of the study:

  • This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hydroxchloroquine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics
  • The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market

Detailed Segmentation:

  • Global Hydroxchloroquine Market, By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
  • Global Hydroxchloroquine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hydroxchloroquine Market, By Region:
    • North America
      • By Disease Indication:
        • Malaria
        • Coronavirus disease (COVID 19)
        • Lupus Erythematosus
        • Rheumatoid Arthritis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Disease Indication:
        • Malaria
        • Coronavirus disease (COVID 19)
        • Lupus Erythematosus
        • Rheumatoid Arthritis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Disease Indication:
        • Malaria
        • Coronavirus disease (COVID 19)
        • Lupus Erythematosus
        • Rheumatoid Arthritis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Disease Indication:
        • Malaria
        • Coronavirus disease (COVID 19)
        • Lupus Erythematosus
        • Rheumatoid Arthritis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Disease Indication:
        • Malaria
        • Coronavirus disease (COVID 19)
        • Lupus Erythematosus
        • Rheumatoid Arthritis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Disease Indication:
        • Malaria
        • Coronavirus disease (COVID 19)
        • Lupus Erythematosus
        • Rheumatoid Arthritis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi S.A.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Amneal Pharmaceuticals, Inc.
    • Laurus Labs Limited
    • Zydus Pharmaceuticals, Inc.
    • Prasco Laboratories
    • Reddy's Laboratories
    • Cadila Pharmaceuticals
    • Novartis International AG
    • Concordia Pharmaceuticals Inc.
    • Covis Pharmaceuticals, Inc.
    • Cardinal Health
    • Aphena Pharma Solutions Tennessee, Inc.
    • Mylan N.V.
    • McKesson Corporation
    • Teva Pharmaceutical Industries Ltd
    • Lupin Pharmaceutical
    • Sun Pharmaceutical Industries Ltd

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Industry Trend
    • Merger and Acquisitions
    • New Disease Indication Approvals/Launch
    • Promotion and Marketing Initiatives
    • PEST Analysis
  4. Global Hydroxychloroquine Market, By Disease Indication, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Malaria
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Coronavirus Disease (COVID 19)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Lupus Erythematosus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Rheumatoid Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Hydroxychloroquine Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Hydroxychloroquine Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Sanofi S.A.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amneal Pharmaceuticals, Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Laurus Labs Limited
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Zydus Pharmaceuticals, Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Prasco Laboratories
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddy's Laboratories
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cadila Pharmaceuticals
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Concordia Pharmaceuticals Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Covis Pharmaceuticals, Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cardinal Health
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aphena Pharma Solutions Tennessee, Inc.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • McKesson Corporation
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Pharmaceutical
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd
        • Company Overview
        • Disease Indication Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 23 market data tables and 18 figures on "Hydroxychloroquine Market” - Global forecast to 2027.

Frequently Asked Questions

The global hydroxychloroquine market size was valued at US$ 484.9 million in 2019 and is estimated to exhibit a CAGR of 45.7% between 2020 and 2027
This report provides in-depth analysis of the global hydroxychloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020 – 2027). The report also provides also provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
Key segments covered in the report include: • Disease Indication • Distribution Channel • Region
Major market dynamics included in the report are drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
Major market drivers for hydroxychloroquine include increasing cases of malaria and rheumatoid arthritis, disease outbreaks such as coronavirus (COVID 19), and approval for extended use of hydroxychloroquine.
The major players operating in the global hydroxychloroquine market include Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Teva Pharmaceutical Industries Ltd, and other prominent players.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner